Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fromm, G. H.
Right arrow Articles by Terrence, C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fromm, G. H.
Right arrow Articles by Terrence, C. F.
NEUROLOGY 1987;37:1725
© 1987 American Academy of Neurology

Comparison of L-baclofen and racernic baclofen in trigeminal neuralgia

Gerhard H. Fromm, MD and Christopher F. Terrence, MD

Department of Neurology (Drs. Fromm and Terrence), University of Pittsburgh School of Medicine, and Neurology Service (Dr. Terrence), Veterans Administration Medical Center, Pittsburgh, PA. Dr. Terrence's present address is the Veterans Administration Medical Center, Newington, CT.

L-Baclofen was compared with racemic baclofen (Lioresal) in a double-blind crossover trial in 15 patients with typical trigeminal neuralgia. L-Baclofen was more effective than five times as much racemic baclofen in nine patients. Six of these nine patients have continued pain-free on L-baclofen for 4 to 17 months (mean, 10 months). L-Baclofen was much better tolerated than racemic baclofen. Our results suggest that L-baclofen represents a significant improvement over racemic baclofen in the treatment of trigeminal neuralgia, and support our laboratory obsemations indicating that D-baclofen antagonizes the action of L-baclofen.

Address correspondence and reprint requests to Dr. Fromm, Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261.

Presented in part at the thirty-eighth annual meeting of the American Academy of Neurology, New Orleans, LA, April 1986.

Received October 20, 1986. Accepted for publication in final form February 9, 1987.




This article has been cited by other articles:


Home page
 J Child NeurolHome page
A. L. Albright
Neurosurgical Treatment of Spasticity and Other Pediatric Movement Disorders
J Child Neurol, January 1, 2003; 18(1_suppl): S67 - S78.
[Abstract] [PDF]

Home page
 DTBHome page
Drug treatment of neuropathic pain
DTB, December 1, 2000; 38(12): 89 - 93.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
G. Broggi, P. Ferroli, A. Franzini, D. Servello, and I. Dones
Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis
J. Neurol. Neurosurg. Psychiatry, January 1, 2000; 68(1): 59 - 64.
[Abstract] [Full Text]

Home page
 J Child NeurolHome page
A. L. Albright
Topical Review: Baclofen in the Treatment of Cerebral Palsy
J Child Neurol, March 1, 1996; 11(2): 77 - 83.
[Abstract] [PDF]

Home page
 Neurorehabil Neural RepairHome page
R. T. Katz
Management of Spastic Hypertonia After Stroke
Neurorehabil Neural Repair, January 1, 1991; 5(5_suppl): S5 - S12.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by AAN Enterprises, Inc.